Influenza
Influenza is an acute respiratory disease caused by influenza viruses, principally viruses in the Orthomyxoviridae family.
Influenza is an acute respiratory disease caused by influenza viruses, principally viruses in the Orthomyxoviridae family. Human disease is caused mainly by Influenza A and influenza B viruses; influenza C generally produces milder illness, while influenza D primarily affects livestock and is not established as a major cause of human disease. influenza A viruses are classified into subtypes according to their surface glycoproteins, including hemagglutinin and neuraminidase. The viral genome consists of multiple segments of negative-sense, single-stranded RNA, enabling genetic reassortment when different influenza A viruses infect the same host cell.
Influenza is transmitted mainly through respiratory droplets and aerosols and infects epithelial cells of the respiratory tract. Viral replication can damage airway epithelium and trigger innate and adaptive immune responses involving cytokines, T-lymphocytes, CD8-positive T-cells, and antibody production. Symptoms commonly include fever, cough, sore throat, myalgia, headache, fatigue, and malaise; gastrointestinal symptoms may occur, particularly in children. Most infections resolve spontaneously, but complications include viral or secondary bacterial pneumonia, exacerbation of chronic cardiopulmonary disease, hospitalization, and death. Risk is increased in older adults, young children, pregnant people, and individuals with conditions such as diabetes or coronary artery disease.
Seasonal influenza vaccination is the principal preventive intervention. Vaccines are formulated to induce antibodies against selected viral antigens, particularly hemagglutinin, and are updated periodically because of antigenic drift. Influenza vaccines may be administered as standalone products or combined with vaccines targeting other respiratory pathogens, including SARS-CoV-2. Antiviral treatment can be used for selected patients, especially those at increased risk of complications or with severe disease. Influenza differs biologically and clinically from COVID-19, which is caused by SARS-CoV-2, although the diseases can overlap in symptoms and may circulate concurrently. respiratory syncytial virus is another distinct respiratory pathogen with overlapping clinical presentations.
Where the papers sit
9 papers from the last 6 months study influenza directly · updated from PubMed 11 Nov 2026
Study type 2 clinical trials · 3 observational · 1 human data · 2 preclinical · 1 unclassified
Themes 3 themes
-
Influenza and COVID-19 Vaccination
Influenza and COVID-19 vaccination is moving toward integrated delivery, combination products, and closer attention to access. Private-sector dispensing data and pharmacists’ views emphasize efficiency, while hospitalization analyses expose ethnic and deprivation inequalities. The mRNA-1083 vaccine extends combination vaccination into multicomponent seasonal immunization, with immunogenicity, reactogenicity, and safety as key endpoints. Wider uptake will depend on whether convenience can be paired with equitable coverage.
4 papers · 44.4%
-
Influenza Antiviral Development
Influenza antiviral development spans combination therapy, host-targeted repurposing, and improved measurement. Favipiravir combined with oseltamivir is being evaluated for safety and efficacy, while ALK inhibitors are being repurposed against influenza and coronaviruses through lymphocyte tyrosine kinase. Hemagglutination and VLP assays support more sensitive virus quantification and standardized testing. Whether these strategies improve recovery beyond established neuraminidase inhibition remains unresolved.
3 papers · 33.3%
-
Seasonal Influenza Vaccine Effectiveness
Seasonal influenza vaccine effectiveness is being measured against laboratory-confirmed infection and hospitalization across children and older adults. Test-negative studies use multivariable logistic regression to estimate protection during the 2025–2026 trivalent vaccine season. Influenza A and B remain important separate outcomes, alongside age-specific differences in hospitalization risk. The work is building current, population-specific estimates rather than establishing a single universal effect size.
2 papers · 22.2%
Papers
The 9 papers from the last 6 months that study influenza directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Influenza and COVID-19 Vaccination (4)
- Pharmacists' perspectives on efficiencies and other benefits of combination influenza/COVID-19 vaccination. Journal of medical economics · 9 Nov 2026 PMID 43001902
- An investigation into post-pandemic ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations. Epidemiology and infection · 26 Oct 2026 PMID 42929057
- Dispensing Patterns of Influenza and Pneumococcal Vaccines in the Private Healthcare Sector in South Africa for 2017 to 2021: A Longitudinal Study. Pharmacoepidemiology and drug safety · 20 Sept 2026 PMID 42764173
- Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
Influenza Antiviral Development (3)
- Microdroplet hemagglutination assay for virus-like particle (VLP) quantification. Lab on a chip · 26 Oct 2026 PMID 42932171
- Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment. BMJ open · 26 Aug 2026 PMID 42648770
- Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
Seasonal Influenza Vaccine Effectiveness (2)
- Effectiveness of the 2025-2026 trivalent influenza vaccine against laboratory-confirmed influenza among older adults in Eastern China: A test-negative case-control study. Human vaccines & immunotherapeutics · 8 Nov 2026 PMID 43000208
- Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026. Infection · 9 Oct 2026 PMID 42853491
By study type
Clinical trials (2)
- Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment. BMJ open · 26 Aug 2026 PMID 42648770
- Immunogenicity, reactogenicity, and safety of an mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine, mRNA-1083, in adults aged ≥50 years in Japan. Vaccine · 30 Jul 2026 PMID 42531981
Observational studies and case reports (3)
- Pharmacists' perspectives on efficiencies and other benefits of combination influenza/COVID-19 vaccination. Journal of medical economics · 9 Nov 2026 PMID 43001902
- Effectiveness of the 2025-2026 trivalent influenza vaccine against laboratory-confirmed influenza among older adults in Eastern China: A test-negative case-control study. Human vaccines & immunotherapeutics · 8 Nov 2026 PMID 43000208
- Dispensing Patterns of Influenza and Pneumococcal Vaccines in the Private Healthcare Sector in South Africa for 2017 to 2021: A Longitudinal Study. Pharmacoepidemiology and drug safety · 20 Sept 2026 PMID 42764173
Human data, design not indexed (1)
- An investigation into post-pandemic ethnic group and deprivation inequalities in influenza and COVID-19 hospitalizations. Epidemiology and infection · 26 Oct 2026 PMID 42929057
Preclinical: animal, cell and lab studies (2)
- Microdroplet hemagglutination assay for virus-like particle (VLP) quantification. Lab on a chip · 26 Oct 2026 PMID 42932171
- Repurposing ALK inhibitors as influenza and corona virus antivirals targeting lymphocyte tyrosine kinase (LTK). Virus research · 9 Jun 2026 PMID 42263913
Unclassified: not yet indexed with MeSH (1)
- Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026. Infection · 9 Oct 2026 PMID 42853491
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-08-20. Drafted by language models from published abstracts; not medical advice.